The FINANCIAL -- The research-based pharmaceutical industry announced donations of 14 billion treatments this decade to support the elimination or control of nine key neglected tropical diseases,according to IFPMA.

The FINNCIAL -- Pfizer announced that the U.S. Food and Drug Administration has accepted its New Drug Application for standard review of bosutinib as a treatment option for adult patients with previously treated Philadelphia chromosome positive chronic myeloid leukemia, according to Pfizer.

The FINANCIAL -- Pharmacyclics, a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune mediated diseases, announced updated results of a Phase Ib/II trial of the selective, irreversible Bruton's tyrosine kinase inhibitor, PCI-32765, for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia small lymphocytic lymphoma .

The FINANCIAL -- Pharmacyclics announced that it has entered into a worldwide collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize PCI-32765, a novel, oral, first-in-class Bruton's tyrosine kinase inhibitor  being developed for the treatment of Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma, all of which are considered hematological malignancies. 

The FINANCIAL -- Pharmacyclics,announced the appointment of Dr. Lori Anne Kunkel as its Chief Medical Officer.   Dr. Kunkel is board certified in hematology, oncology and internal medicine and will provide strategic input and oversight into the company's clinical development programs and medical affairs.